AAHRPP Accredits First Organization in China
The Association for the Accreditation of Human Research Protection Programs (AAHRPP) announced that it has awarded five organizations with Full Accreditation. Setting new milestones, in its tenth year, AAHRPP has accredited its first organization in China, first psychiatric hospital, and first federal central IRB. The list also includes two top medical colleges and teaching hospital. Specifically, the following were accredited:
- Beijing YouAn Hospital, Capital Medical University, Beijing, China
- McLean Hospital, Belmont, MA
- Mount Sinai School of Medicine and The Mount Sinai Hospital, New York, NY
- The Medical College of Wisconsin, Inc. and Froedtert Memorial Lutheran Hospital, Inc., Milwaukee, WI
- Veterans Health Administration Central Office Human Research Protections Program, Washington, DC
"We are pleased to accredit our first human research protection program at the Beijing YouAn Hospital, Capital Medical University. With China's rapid expansion into clinical trial research we are confident that Beijing YouAn Hospital, Capital Medical University will lead the way for other Chinese institutions to put human safety and wellbeing first by becoming accredited." said Marjorie A. Speers, Ph.D., President and CEO, AAHRPP. Also among first are McLean Hospital and the Veterans Health Administration Central Office Human Research Protections Program, a federal central IRB that reviews multisite studies funded by VA and conducted at local VA facilities. Through the rigorous accreditation process, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to the highest standards for research. The accreditation process typically results in system-wide improvements that enhance protections for research participants and promote high-quality research. Accreditation is available to organizations world-wide that conduct biomedical, behavioral or social sciences research involving human participants.Decisions on accreditation are announced quarterly, and accreditation is valid for three years.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
